PMID: 6104837Jan 1, 1980Paper

Neuroleptic-induced acute dyskinesias in squirrel monkeys: correlation with propensity to cause extrapyramidal side effects

Psychopharmacology
J Liebman, R Neale

Abstract

In squirrel monkeys that had undergone repeated treatment with haloperidol at intervals of 7--14 days, subsequent acute administration of haloperidol induced dystonia and dyskinesias. This acute effect of haloperidol was dose-related and occurred at the same doses that impaired Sidman avoidance performance. Chlorpromazine, fluphenazine, metoclopramide, tetrabenazine, and Su-23397, all of which have been associated with extrapyramidal side effects, reliably elicited dyskinesias in these monkeys. Dyskinesias were less mared after thioridazine and absent after clozapine, corresponding to the reported lower incidence of extrapyramidal side effects in the clinic. The non-neuroleptics, baclofen, and diazepam, failed to elicit dyskinesias. In contrast to the dyskinetic syndrome, the incidence of catalepsy or tremor did not accurately predict propensity to elicit extrapyramidal symptomatology. The acute dyskinetic syndrome in squirrel monkeys may therefore serve as an animal model for predicting the ability of antipsychotics to cause extrapyramidal dysfunction, and may yield insight into the mechanisms of these drug-induced motor disorders.

References

Aug 15, 1978·European Journal of Pharmacology·J LiebmanN J Moen
Aug 1, 1978·The British Journal of Psychiatry : the Journal of Mental Science·M AlpertA J Friedhoff
Jun 1, 1977·Brain : a Journal of Neurology·B S MeldrumC D Marsden
Aug 16, 1977·Psychopharmacology·B WeissG Lusink
Jan 1, 1978·Neuropsychobiology·D De MaioG Scieghi
Nov 24, 1976·Psychopharmacology·L M Gunne, S Bárány
May 11, 1975·The American Journal of Psychiatry·C Swett

❮ Previous
Next ❯

Citations

Jan 1, 1981·Psychopharmacology·R D Porsolt, M Jalfre
Jan 1, 1984·Psychopharmacology·B Kovacic, E F Domino
Aug 1, 1983·Brain Research Bulletin·R L Borison, B I Diamond
Feb 20, 2003·European Journal of Pharmacology·Rakesh KumarBhola N Dhawan
Jan 4, 1998·Pharmacology, Biochemistry, and Behavior·T FukuokaM Matsuo
Jul 27, 1999·Pharmacology, Biochemistry, and Behavior·R E SteinpreisC K Kruschel
Nov 14, 1997·Neuroscience and Biobehavioral Reviews·S A JosselynR J Beninger
Aug 25, 2004·The Australian and New Zealand Journal of Psychiatry·Pierre BeumontUNKNOWN Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Anorexia Nervosa
Dec 1, 1991·The Japanese Journal of Psychiatry and Neurology·J NakamuraK Inanaga
Aug 26, 1998·Reviews in the Neurosciences·E BezardC E Gross
Mar 29, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Rebecka KlintenbergPer E Andrén
Jan 1, 1981·Acta Psychiatrica Scandinavica. Supplementum·K E Moore
Dec 4, 2003·Journal of Pharmacological Sciences·Yasuyuki ShiigiDaniel E Casey
Dec 1, 1994·The British Journal of Psychiatry : the Journal of Mental Science·D K Arya
Sep 14, 2013·The Journal of Pharmacology and Experimental Therapeutics·Roger D PorsoltDavid Virley
Feb 1, 1986·Annals of Neurology·M Rodriguez, H C Powell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here